<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1595">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05140395</url>
  </required_header>
  <id_info>
    <org_study_id>CPSP_20-01_V1</org_study_id>
    <nct_id>NCT05140395</nct_id>
  </id_info>
  <brief_title>ABTEST© Card Clinical Perfomance Study</brief_title>
  <official_title>Clinical Perfomance Study of the ABTEST© Card in Vitro Medical Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diagast</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diagast</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study confirms the performance equivalence of the in vitro Diagnostic reagent ABTEST card&#xD;
      used with the new reformulated WS solution&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists to perform on 100 patients a first pre transfusional control with the&#xD;
      reference in vitro reagent ABTEST card (CE Marked reagent) followed by a another pre&#xD;
      transfusional control with the in vitro reagent ABTEST card in study (new reformulated WS&#xD;
      solution used) .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 6, 2021</start_date>
  <completion_date type="Actual">November 4, 2021</completion_date>
  <primary_completion_date type="Actual">October 28, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>in situ used for near patient In vitro Medical device</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Agreement between two reagents</measure>
    <time_frame>5 minutes</time_frame>
    <description>performance of pre transfusional controls with the referent reagent and the reagent in study</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Transfusion Reaction</condition>
  <arm_group>
    <arm_group_label>Pre transfusion control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre control transfusion with the referent reagent and the in study reagent</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ABTEST card</intervention_name>
    <description>Pre transfusional control with the referent ABTEST card and the in study ABDTEST Card</description>
    <arm_group_label>Pre transfusion control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        66 patients in hematology / oncology departments , including 20 patients with a hemoglobin&#xD;
        significantly below the norm (&lt;8g / dl hemoglobin in the blood), and about to receive a&#xD;
        transfusion. 20 patients hospitalized in gastroenterology with a transfusion need 4&#xD;
        internal medicine patients with cold agglutinins, in a transfusion context or not.&#xD;
&#xD;
        10 neonatal patients, background transfusion or Guthrie test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal Huchette, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Arras</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH Arras</name>
      <address>
        <city>Arras</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Reagent Kits, Diagnostic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Transfusion Reaction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

